Is This the Year Exelixis Excels?
The lack of early success in its lead drug's cancer trial scares the market, but we see a buying opportunity.
Exelixis (EXEL) announced this week that after a prespecified interim analysis for Cometriq's Phase III COMET-1 trial in prostate cancer patients, the independent data monitoring committee concluded the trial should continue to its final analysis. While the trial could have been stopped early at this interim analysis for success, we were not expecting this best-case scenario. Nevertheless, the stock sold off significantly on the news, probably because several other recent prostate cancer trials (Johnson & Johnson's Zytiga, Medivation's Xtandi and Bayer's Xofigo) were stopped early due to success.
We continue to believe that Cometriq has a 50% chance of success in the trial, and we are maintaining our $7.50 fair value estimate and no-moat rating for Exelixis. While the stock had been trading around our fair value estimate, we think the recent sell-off provides an opportunity to invest at a significant discount, with the key potential catalyst of the final COMET-1 results still expected later in 2014.
Stefan Quenneville, CFA does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.